Clinical trial · Observational
Long-term Assessment of Chlormethine Gel in Mycosis Fungoides
Long-term Assessment of Chlormethine Gel in Mycosis Fungoides: A Multicenter Retrospective Cohort Study
NCT07046663CI-TRIAL-00091776FIL_CLOR-CTCLnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to provide comprehensive insights into the long-term therapeutic outcomes, potential adverse effects, and overall patient experience with chlormethine gel, thereby informing clinical practice and guiding future treatment strategies for mycosis fungoides.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Mycosis Fungoides | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients who started treatment with chlormethine gel, from September 1, 2019 to September 30, 2024
Primary outcomes (1)
- measure
- Rate of complete remission (rate CR)
- timeFrame
- Up to 12 months
- description
- Rate of complete remission (rate CR) according to CAILS and mCAILS tools and mSWAT after 6 months from the start of treatment
Secondary outcomes (7)
- measure
- Percentage of CR and ORR (CR+PR)
- timeFrame
- Up to 12 months
- description
- Percentage after 3, 6 and 12 months from start of treatment of CR and ORR (CR+PR)
- measure
- Nelson-Aalen estimation
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients age ≥ 18 * Histologically confirmed diagnosis of MF based on WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition * Patients who are capable of understanding and willing, and able to read and write in Italian * Patients who have signed informed consent form * Patients who started treatment with chlormethine gel, from September 1, 2019 to September 30, 2024. * Patients must have a minimum follow-up period of 6 months following the initiation of chlormethine treatment. * Availability of complete medical records in order to provide protocol required variables. Exclusion Criteria: * Patients for whom retrospective data or information on the type of therapy, duration, and clinical outcomes are not available in the center's medical records. * Refuse to sign a written informed consent. * Patients not meeting the above-mentioned inclusion criteria
References
Publications (0)
Data not yet available
No reference posted for this study.